Pfizer settles Biohaven kickback case with DOJ
Pfizer CEO Albert Bourla joins CNBC's 'Special Report' as President-elect Donald Trump is inaugurated as the 47th U.S.
The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.
Pfizer Inc. closed 16.17% below its 52-week high of $31.54, which the company achieved on July 30th.
At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...
Oklahoma City Indian Clinic announced it has received a $250,000 charitable contribution from Pfizer to support programs ...
The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the ...
In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...
U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...
The sale decreases Pfizer’s shareholding in the consumer-healthcare business to 7.3% of its issued share capital, down from ...
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 50% bearish. Among these notable ...
Mr Bourla does not say in the interview that COVID jabs are dangerous. The interview begins at the 35 seconds mark of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback